Cart
sales@molnova.com
DpC
CAS No. 1382469-39-7
DpC( —— )
Catalog No. M36990 CAS No. 1382469-39-7
DPC is an antitumor compound that inhibits cancer cell proliferation with an IC50 of 0.007-0.096 μM.DPC is involved in a variety of anticancer therapies and can be used in cancer research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 46 | Get Quote |
|
| 5MG | 65 | Get Quote |
|
| 10MG | 103 | Get Quote |
|
| 25MG | 204 | Get Quote |
|
| 50MG | 327 | Get Quote |
|
| 100MG | 473 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameDpC
-
NoteResearch use only, not for human use.
-
Brief DescriptionDPC is an antitumor compound that inhibits cancer cell proliferation with an IC50 of 0.007-0.096 μM.DPC is involved in a variety of anticancer therapies and can be used in cancer research.
-
DescriptionDpC is an anti-tumor agent. DpC inhibits cancer cell proliferation (IC50: 0.007-0.096 M). DpC synergizes with multiple anti-cancer therapeutics.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1382469-39-7
-
Formula Weight353.48
-
Molecular FormulaC19H23N5S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (176.81 mM; Ultrasonic )
-
SMILESC(=NNC(N(C)C1CCCCC1)=S)(C2=CC=CC=N2)C3=CC=CC=N3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Dharmasivam M, et al. The thiosemicarbazone, DpC, broadly synergizes with multiple anti-cancer therapeutics and demonstrates temperature- and energy-dependent uptake by tumor cells. Biochim Biophys Acta Gen Subj. 2022 Aug;1866(8):130152.?
molnova catalog
related products
-
Trovafloxacin mesyla...
Trovafloxacin mesylate is an effective and selective inhibitor of pannexin 1 channel (PANX1, IC50 = 4 μM).
-
Lytic Peptide, Shiva...
Lytic Peptide, Shiva – 1
-
Burosumab
Burosumab(KRN23) is a human monoclonal antibody targeting fibroblast growth factor 23 (FGF23) for the treatment of cutaneous-skeletal hypophosphatemic syndrome (CSHS) and tumor-induced osteochondrosis.
